11 September 2020
Sydney's iconic Sun-Herald City2Surf 2020 is on Sunday 18 October 2020, it’s the 50th anniversary and this year the event is virtual, so more people can join in!
Hand sanitiser, social distancing, isolation, working from home…It’s all part of our ’new normal’. For events, the ‘new normal’ means a virtual event. It’s the perfect excuse to get a few mates together, enjoy the day and run, jog or walk 14kms in your neighbourhood to your own beat.
How does the virtual event work?
- Once you've registered you’ll receive an email with a link to download the C2S app
- Anytime between 6am and 6pm* on Sunday 18 October 2020, just open the C2S app and push ‘Start’. You’ll be tracked as if you're doing the actual C2S course - no matter where you are. (*MIA recommend avoiding the middle of the day when the UV rating is higher.)
- When you hit 14kms, the tracking will stop automatically, and your result will be submitted
- Be part of history! All finishers will receive C2S 50 year ‘bling’ (medal) and an exclusive 2020 bandana.
You’re invited to be a Charity Superstar!
Giving back to charity is the beating heart of City2Surf. Melanoma Institute Australia has 20 Charity Superstar places available to our fundraisers. We invite you to become one of 20 MIA Charity Superstars for this year’s City2Surf.
As a Charity Superstar you’ll be part of an exclusive group helping Melanoma Institute Australia achieve our mission of zero deaths from melanoma this decade. You’ll receive the following benefits:
- We’ll cover your C2S entry fee
- You’ll receive a ‘Run over Melanoma’ singlet, MIA hat and SunSense sunscreen
- Be part of the MIA and make a real difference for people impacted by melanoma
- Be rewarded for achieving your fundraising target of $1000 (we’ll support you!)
To apply to become a C2S Charity Superstar please click on the link below:
Together we can run over melanoma!
Visit the City2Surf website for more information about participating in this iconic event.
#City2Surf #LetsRunSydney #RunOverMelanoma.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.